SRC and Duchenne muscular dystrophy: The potent anticancer agent dasatinib (DAS) has recently gained interest for its possible repurposing in children with DMD, in virtue of its ability to prevent tyrosine phosphorylation and degradation of β-DG, via inhibition of ROS-activated cSrc TK.